Overview

A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs

Status:
Completed

Trial end date:
2017-11-22

Target enrollment:

Participant gender:

Summary

The objective of this study was to verify the superiority of ASP015K alone or in combination with disease-modifying antirheumatic drugs (DMARDs) over placebo in terms of efficacy in participants with rheumatoid arthritis (RA) who had an inadequate response to DMARDs

Phase:

Phase 3

Details

Lead Sponsor:

Astellas Pharma Inc

Treatments:

Etanercept
Peficitinib